Competitors in the market for the treatment of coronary artery disease must face a litany of alternative technologies targeted at this patient caseload. Despite the successes of drug-eluting stents in producing results that are cost- and outcome-competitive compared to coronary artery bypass grafting, the drive for less invasive alternatives, improved clinincal outcomes and other benefits will continue to produce technology alternatives.
In addition to drug-eluting, bare metal and bioresorbable coronary stents, a range of novel stent technologies are under development in the market:
- bioactive coatings
- antibody coatings
- biomimetic coatings (biocompatible and thromboresistant)
- hydrophilic coatings to facilitate stent delivery
- titanium-nitride-oxide coating
- genetically engineered bioactive
- coatings to induce endothelial cell growth
- pericardium-covered stents
- beta-radiation emitting stents
- polymer coatings engineered to be pulsatile, biostable
- anti-thrombotic, anti-inflammatory, bacterial-resistant coating
- stents engineered with embolic protection capability
Development is also not limited to the above stent technologies, as technologies for drug-eluting balloons, robotic CABG and a wide range of other technologies are the focus of many competitors seeking to displace some of the billions of dollars spend on coronary stents.
See the May 2009 MedMarket Diligence report #C245, "Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017."